Allovir, Inc. ALVR
We take great care to ensure that the data presented and summarized in this overview for Allovir, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALVR
View all-
Siren, L.L.C. New York, NY6.6MShares$63.5 Million0.12% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.03MShares$29.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$25.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA1.91MShares$18.4 Million0.06% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ664KShares$6.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY634KShares$6.11 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA585KShares$5.63 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA552KShares$5.32 Million0.02% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny497KShares$4.78 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA452KShares$4.35 Million0.0% of portfolio
Latest Institutional Activity in ALVR
Top Purchases
Top Sells
About ALVR
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Insider Transactions at ALVR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2025
|
Brett R Hagen Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
36
-0.61%
|
$324
$9.7 P/Share
|
|
Jan 23
2025
|
Edward Miller General Counsel |
SELL
Open market or private sale
|
Direct |
52
-0.39%
|
$468
$9.7 P/Share
|
|
Jan 23
2025
|
Vikas Sinha |
SELL
Open market or private sale
|
Direct |
129
-0.13%
|
$1,161
$9.7 P/Share
|
|
Jan 10
2025
|
Vikas Sinha |
SELL
Open market or private sale
|
Direct |
979
-0.09%
|
$0
$0.44 P/Share
|
|
Jan 10
2025
|
Brett R Hagen Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
332
-0.48%
|
$0
$0.44 P/Share
|
|
Jan 10
2025
|
Edward Miller General Counsel |
SELL
Open market or private sale
|
Direct |
409
-0.27%
|
$0
$0.44 P/Share
|
|
Dec 11
2024
|
Edward Miller General Counsel |
BUY
Bona fide gift
|
Indirect |
57,549
+14.25%
|
-
|
|
Dec 11
2024
|
Edward Miller General Counsel |
SELL
Bona fide gift
|
Direct |
57,549
-27.21%
|
-
|
|
Nov 19
2024
|
Diana Brainard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,706
-1.19%
|
$0
$0.55 P/Share
|
|
Nov 19
2024
|
Edward Miller General Counsel |
SELL
Open market or private sale
|
Direct |
432
-0.2%
|
$0
$0.55 P/Share
|
|
Nov 19
2024
|
Vikas Sinha |
SELL
Open market or private sale
|
Direct |
3,186
-0.28%
|
$0
$0.55 P/Share
|
|
Nov 19
2024
|
Brett R Hagen Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
554
-0.8%
|
$0
$0.55 P/Share
|
|
Nov 05
2024
|
Vikas Sinha |
SELL
Open market or private sale
|
Direct |
5,136
-0.45%
|
$0
$0.86 P/Share
|
|
Nov 05
2024
|
Brett R Hagen Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,655
-2.34%
|
$0
$0.86 P/Share
|
|
Nov 05
2024
|
Edward Miller General Counsel |
SELL
Open market or private sale
|
Direct |
2,272
-1.06%
|
$0
$0.86 P/Share
|
|
Nov 05
2024
|
Diana Brainard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,609
-1.43%
|
$0
$0.86 P/Share
|
|
Oct 22
2024
|
Edward Miller General Counsel |
SELL
Open market or private sale
|
Direct |
766
-0.36%
|
$0
$0.77 P/Share
|
|
Oct 22
2024
|
Brett R Hagen Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
486
-0.68%
|
$0
$0.77 P/Share
|
|
Oct 22
2024
|
Vikas Sinha |
SELL
Open market or private sale
|
Direct |
1,882
-0.16%
|
$0
$0.77 P/Share
|
|
Oct 21
2024
|
Edward Miller General Counsel |
SELL
Open market or private sale
|
Direct |
635
-0.29%
|
$0
$0.78 P/Share
|
Last 12 Months Summary
| Bona fide gift | 57.5K shares |
|---|---|
| Grant, award, or other acquisition | 245K shares |
| Open market or private sale | 154K shares |
|---|---|
| Bona fide gift | 57.5K shares |